Literature DB >> 20622963

Role of loss of o⁶-methylguanine dna methyltransferase (MGMT) expression in non-small cell lung carcinomas (NSCLCs): with reference to the relationship with p53 overexpression.

Na-Hye Myong1.   

Abstract

PURPOSE: Functional inactivation of the O⁶-methylguanine-DNA methyltransferase (MGMT) gene has been demonstrated as loss of MGMT protein and suggested that it plays an important role in primary human neoplasia, including lung cancer. It has also been reported to be associated with the G : C-->A : T transition mutation in the p53 gene of lung cancer. The aims of this study were to investigate the role of MGMT expression loss and its prognostic significance in non-small cell lung carcinomas (NSCLCs), and its correlation with p53 overexpression as well as influence on patient survival.
MATERIALS AND METHODS: 112 surgically resected NSCLC specimens were reviewed by medical records for their clinicopathologic variables. Their tissue microarray blocks were immunostained with anti-human MGMT and p53 primary antibodies. Correlation between MGMT loss and the clinicopathologic prognostic factors, including p53 overexpression and the single or combined actions of MGMT loss and p53 overexpression on patient survival were statistically analyzed by SPSS15.0.
RESULTS: Reduced or absent MGMT expression was found in 48 of 112 NSCLCs (43%), and significantly associated with nodal metastasis and squamous or undifferentiated cell types. Loss of MGMT expression was correlated with p53 overexpression in adenocarcinomas, but not in overall NSCLCs. Its solitary or combined actions with p53 overexpression did not have influence on patient survival.
CONCLUSION: Loss of MGMT expression is a relatively common event in NSCLCs and significantly associated with nodal metastasis and p53 overexpression, suggesting that it may play a major role in pulmonary carcinogenesis, and also in disease progression of NSCLCs.

Entities:  

Keywords:  Carcinogenesis; Disease progression; MGMT protein; Non-small-cell lung carcinomas (NSCLCs); p53 protein

Year:  2010        PMID: 20622963      PMCID: PMC2901077          DOI: 10.4143/crt.2010.42.2.95

Source DB:  PubMed          Journal:  Cancer Res Treat        ISSN: 1598-2998            Impact factor:   4.679


  19 in total

1.  O(6)-Methylguanine-DNA methyltransferase promoter hypermethylation shifts the p53 mutational spectrum in non-small cell lung cancer.

Authors:  P Wolf; Y C Hu; K Doffek; D Sidransky; S A Ahrendt
Journal:  Cancer Res       Date:  2001-11-15       Impact factor: 12.701

2.  MGMT expression in oral precancerous and cancerous lesions: correlation with progression, nodal metastasis and poor prognosis.

Authors:  Meenakshi Sawhney; Nidhi Rohatgi; Jatinder Kaur; Siddhartha D Gupta; Suryanaryana V S Deo; Nootan K Shukla; Ranju Ralhan
Journal:  Oral Oncol       Date:  2006-09-25       Impact factor: 5.337

3.  Methylation hot spots in the 5' flanking region denote silencing of the O6-methylguanine-DNA methyltransferase gene.

Authors:  X C Qian; T P Brent
Journal:  Cancer Res       Date:  1997-09-01       Impact factor: 12.701

Review 4.  Alterations in DNA methylation: a fundamental aspect of neoplasia.

Authors:  S B Baylin; J G Herman; J R Graff; P M Vertino; J P Issa
Journal:  Adv Cancer Res       Date:  1998       Impact factor: 6.242

5.  Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia.

Authors:  M Esteller; S R Hamilton; P C Burger; S B Baylin; J G Herman
Journal:  Cancer Res       Date:  1999-02-15       Impact factor: 12.701

Review 6.  Cancer epigenetics comes of age.

Authors:  P A Jones; P W Laird
Journal:  Nat Genet       Date:  1999-02       Impact factor: 38.330

7.  DNA methylation in tumor and matched normal tissues from non-small cell lung cancer patients.

Authors:  Qinghua Feng; Stephen E Hawes; Joshua E Stern; Linda Wiens; Hiep Lu; Zhao Ming Dong; C Diana Jordan; Nancy B Kiviat; Hubert Vesselle
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-03       Impact factor: 4.254

8.  Promoter methylation of O(6)-methylguanine-DNA-methyltransferase in lung cancer is regulated by p53.

Authors:  Ji-Ching Lai; Ya-Wen Cheng; Yih-Gang Goan; Jinghua Tsai Chang; Tzu-Chin Wu; Chih-Yi Chen; Huei Lee
Journal:  DNA Repair (Amst)       Date:  2008-06-13

9.  Promoter methylation primarily occurs in tumor cells of patients with non-small cell lung cancer.

Authors:  Wouter K De Jong; Gonda F Verpooten; Henk Kramer; Joost Louwagie; Harry J M Groen
Journal:  Anticancer Res       Date:  2009-01       Impact factor: 2.480

10.  Prognostic significance of DNA repair proteins MLH1, MSH2 and MGMT expression in non-small-cell lung cancer and precursor lesions.

Authors:  W A Cooper; M R J Kohonen-Corish; C Chan; S Y Kwun; B McCaughan; C Kennedy; R L Sutherland; C-S Lee
Journal:  Histopathology       Date:  2008-04       Impact factor: 5.087

View more
  3 in total

1.  Relationship Between the Expression of O6-Methylguanine-DNA Methyltransferase (MGMT) and p53, and the Clinical Response in Metastatic Pancreatic Adenocarcinoma Treated with FOLFIRINOX.

Authors:  Carole Vitellius; Caroline Eymerit-Morin; Dominique Luet; Lionel Fizanne; Fanny Foubert; Sandrine Bertrais; Marie-Christine Rousselet; François-Xavier Caroli-Bosc
Journal:  Clin Drug Investig       Date:  2017-07       Impact factor: 2.859

2.  Immunohistochemical Assessment of O(6)-Methylguanine-DNA Methyltransferase (MGMT) and Its Relationship with p53 Expression in Endometrial Cancers.

Authors:  Kyung Eun Lee
Journal:  J Cancer Prev       Date:  2013-12

3.  Expression profiling of O(6) methylguanine-DNA-methyl transferase in prolactinomas: a correlative study of promoter methylation and pathological features in 136 cases.

Authors:  Xiao-Bing Jiang; Bin Hu; Dong-Sheng He; Zhi-Gang Mao; Xin Wang; Bing-Bing Song; Yong-Hong Zhu; Hai-Jun Wang
Journal:  BMC Cancer       Date:  2015-09-23       Impact factor: 4.430

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.